InflaRx shares surge 73.17% premarket after positive Phase 2a INF904 data for HS and CSU.

InflaRx surged 73.17% in premarket trading following the release of positive Phase 2a clinical trial data for INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). The trial demonstrated rapid, dose-dependent reductions in lesion counts, pain, and inflammatory markers, with no serious adverse events reported. INF904 showed HiSCR50 responses in 28% of HS patients at 4 weeks, with efficacy persisting post-treatment, and a -13.7 UAS7 score reduction in CSU patients, exceeding historical placebo benchmarks. The company highlighted INF904’s potential as a "pipeline-in-a-product" with a $1 billion addressable market and plans to initiate Phase 2b trials in HS by 2026. Strong clinical performance, safety profile, and development timelines aligned with investor optimism, driving the sharp premarket rally.